Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …

Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

In the past decade, nonalcoholic fatty liver disease (NAFLD) has become a leading cause of
chronic liver disease and cirrhosis, as well as an important risk factor for hepatocellular …

Background and Aims Nonalcoholic steatohepatitis is rapidly becoming the leading cause of
liver failure and indication for liver transplantation. Hepatic inflammation is a key feature of …

Liver fibrosis, as an excess deposition of extracellular matrix (ECM) components, results
from chronic liver injury as well as persistent activation of inflammatory response and of …

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an unabated risk factor
for end-stage liver diseases with no available therapies. Dysregulated immune responses …

Non-alcoholic fatty liver disease (NAFLD) with its more progressive form non-alcoholic
steatohepatitis (NASH) has become the most common chronic liver disease, thereby …

Diabetes-associated morbidity and mortality is predominantly due to complications of the
disease that may cause debilitating conditions, such as heart and renal failure, hepatic …

Liver fibrosis is a common pathological feature of end stage liver failure, a severe life-
threatening disease worldwide. Nonalcoholic fatty liver disease (NAFLD), especially its more …